Recently revised UK and US hypertension guidelines have reduced thresholds for both diagnosis and treatment and differ in their recommendations. We have used data from a random, stratified community-based sample of 4784 people aged 65 years and over to compare the prevalence of treatable hypertension and the potential impact on patients and primary care from using current guidelines. BHS, NICE and JNC7 guidelines were applied to blood pressures obtained from primary care medical records (94%) or measured at a screening clinic (6%). Risk factors were obtained by questionnaire and from medical records, supplemented by epidemiological data. Workload was estimated for a representative practice population of 10 000 patients. Blood pressures were obtained on 4514 patients (94%). Prevalence of treatable hypertension was over 67%. Compared to BHS4, prevalence estimates using NICE guidelines were comparable for men but significantly lower for women (Po0.05). They were significantly higher using JNC7 compared with BHS4 and NICE guidance (Po0.05). A general practice of 10 000 patients could expect 1287 older hypertensive patients using BHS4 guidelines and 1231 patients using NICE guidelines. Under BHS4, an extra 94 patients will require annual, rather than 5-yearly review compared with that using the previous guideline. In conclusion, implementation of BHS4 guidelines, with their revised thresholds for diagnosis, will not add materially to the prevalence of treatable hypertension compared to previous BHS3 guidelines but will have a major impact on practice workload. Use of NICE guidelines in preference to BHS4 will result in GPs treating fewer patients and reviewing untreated patients less often.
Introduction
National guidelines for hypertension have often been criticised for the variation shown between them, particularly in terms of treatment thresholds and drug therapy. 1 The 1999 British Hypertension Society (BHS) Guidelines (3rd issue) recommended that, in persons with mild hypertension, treatment should be initiated if the 10-year coronary heart disease (CHD) risk exceeded 15%. 2, 3 However, the recently published BHS4 and National Institute for Clinical Excellence (NICE) guidelines recommend treatment be instigated if the 10-year cardiovascular disease (CVD) risk, incorporating both ischaemic heart disease and stroke, exceeds 20%. 4, 5 The BHS3 guidelines 3 have been promoted widely and in the UK are reflected in health policy initiatives such as the UK's National Service Frameworks for older people (stroke), 6 CHD, 7 and diabetes. 8 A study to assess the cost-effectiveness of BHS3 guidelines for new patients in primary care concluded that their implementation would be more expensive, but more effective in reducing cardiovascular risk compared with earlier guidelines. 9 The BHS3 guideline has now been superseded 4 and further recent guidance issued from NICE 5 redefines and lowers the thresholds for diagnosis and treatment based on a patient's absolute risk. 4, 5 Previously, when BHS3 guidelines were introduced, concerns were expressed about the capacity of primary care to meet the then new demands and hence the capacity to maintain improvements in treatment as defined by earlier guidance. 10 Similarly, following release of BHS4 there has been disquiet expressed regarding prescribing budgets and GP workload. 11, 12 Nonetheless, there is little epidemiological data to quantify the size of this perceived problem, particularly in older people who are at higher absolute risk of CVD. We have analysed data collected on a representative community-based sample of older people aged 65 years and over in order to assess the prevalence and treatment implications of hypertension when applying the latest guidelines. We have also compared this with earlier BHS3 guidelines to give a measure of the additional impact on GP workload of the newer guidelines. Finally, we have compared the latest UK and US guidelines (Joint National Committee, JNC7) 13 to determine the difference in prevalence of diagnosed hypertension using the same data in order to explore international dimensions.
Materials and methods
This study is a secondary analysis of data collected from a previous study that was approved by the Northumberland Research Ethics Committee. The patient population was a random, stratified sample of 4784 people aged 65 years and over, resident in south east Northumberland and registered with one of 27 contiguous general practices.
14 Data were obtained from self-completion questionnaires, primary care medical records and a screening clinic using standardised definitions. Blood pressure was taken as the mean of the last three blood pressure readings recorded in the medical record prior to the screening clinic (1995/97). This method is consistent with other studies of pragmatic blood pressure diagnosis and treatment in primary care. 15 Missing data were supplemented by blood pressures measured at the screening clinic using methods recommended by the BHS. 16 Medication was obtained by self-report and computerised GP prescribing data. Patients taking antihypertensive drugs were identified and the reason for treatment determined.
We classified patients as hypertensive if they were previously diagnosed as hypertensive and taking drug treatment for their hypertension. At the time of the study (1995/97) GP practices were working to the local Northumberland guidelines. 17 Additionally, patients were defined as hypertensive if their blood pressure measurements fell above the threshold for diagnosis and treatment as defined by the BHS3, BHS4, NICE and JNC7 guidelines (Table 1) . Additional data were used to categorise patients into 20 For those patients who did not have a cholesterol measure and for whom we could not determine whether the CVD risk exceeded the guideline threshold, we estimated the proportions that would exceed the 20% threshold using data from the 1998 Health Survey for England. 21 The JNC7 guidelines recommend treatment for persons with defined blood pressures who also have renal disease. Estimation of the number of such persons was made from NHANES data on the distribution of creatinine levels with a value of 41.5 mg/l indicating the presence of renal disease. 22 The prevalence of hypertension was then constructed from the above estimates by adding the already diagnosed and treated hypertensive patients to those newly identified, untreated hypertensives as defined by the criteria in each guideline. The mean difference and 95% confidence interval of the difference in prevalence was calculated comparing the guidelines.
Management decisions were compared in those patients with complete data but not on current treatment to establish the degree of equity between use of BHS4 and NICE guidelines.
Finally, the prevalence estimates using BHS3, BHS4 and NICE were applied to a GP practice of 10 000 patients having the age/sex distribution of the source Northumberland population to determine the impact on workload arising from changing to applying BHS4 guidelines (compared to BHS3), and the difference between implementing BHS4 and NICE guidelines.
Results
Data were available for 4514 patients (94% of the target sample) and blood pressures obtained in 4221 patients (94%) from primary care records and an additional 293 patients (6%) from a screening clinic.
The number of patients on treatment for hypertension and, for all those not being treated, the number (and proportion) of patients that smoked, had total cholesterol measured, target organ damage and incomplete data are given in Table 2 . The number of patients with incomplete data for which estimates were made of either the proportion with raised cholesterol levels, or with raised creatinine levels (indicative of renal disease) varied according to each guideline. Overall, only a minority of patients had incomplete data, which precluded assigning them individually to a diagnostic category.
The prevalence of treatable hypertension was very high (Table 3) . For 65-74-year-old men and women the prevalence was 70.4 and 73.3%, respectively, with BHS4 guidelines and had only increased marginally compared to the prevalence as deter- Patients with prehypertension in whom prevalence of renal disease was estimated.
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Hypertension guidelines R Thomson et al mined using the older BHS3 guidelines. For those over 75 years the prevalence using BHS4 guidelines was 74.4 and 84.3% for men and women, respectively and, again, had increased only marginally compared with the earlier BHS3 guidelines. Compared to BHS4 guidelines the prevalence estimates using NICE (2004) guidelines were comparable for men but significantly lower for women (Po0.05). Prevalence estimates were highest using JNC7 guidance and for most comparisons with BHS4 and NICE the differences were significant at Po0.05 (Table 3) . We compared management decisions using BHS4 and NICE guidelines in a subset of 2098 patients with complete data (59% of those not on current treatment). In this subset, 2003 (95.4%) would require treatment for hypertension using BHS4 and 1864 (88.8%) using NICE. A total of 1823 (86.9%) would be recommended for treatment under both guidelines, and only 54 (2.6%) by neither guideline.
In all, (2.0%) would be treated by applying NICE but not BHS4, and 180 (8.6%) treated using BHS4 but not NICE guidance. One key difference between BHS4 and NICE guidelines relates to the threshold for defining a raised blood pressure (Table 1) . Under BHS4, treatment should be considered for those with a blood pressure of 140/90 mmHg or more whereas NICE recommends treatment be considered for those with a blood pressure of greater than 140/90. In this subgroup of 180 patients, 102 (57%) had a systolic blood pressure of 140 mmHg or a diastolic blood pressure of 90 mmHg whereby they would be considered treatable by BHS4 but not by NICE criteria defining hypertension.
Finally, the impact on GP workload from applying BHS3, BHS4 or NICE guidelines is given in Table 4 for patients aged 65 years or over in a general practice of 10 000 patients with the age and sex distribution of Northumberland. Adoption of BHS4 over BHS3 guidelines results in marginally more patients being treated but much larger numbers requiring annual, rather than 5-yearly review. Use of the NICE guidelines in preference to BHS4 would result in fewer patients requiring treatment and many fewer patients being seen annually (Figure 1) .
Discussion
This study derives from an extensive, representative population-based survey of patients aged 65 years or older and has revealed the considerable challenges facing general practice in meeting the demands of the latest hypertension guidelines 4, 5 and the UK National Service Frameworks. [6] [7] [8] The prevalence of treatable hypertension in older persons is very high with consequent impact on prescribing costs and practice workload that will be greater using BHS4 rather than NICE guidelines. Earlier concerns expressed about the applicability and implications for primary care of BHS3 guidelines published in 1999 remain well-founded, at least for patients over 65 years. There are some limitations to the data presented, but they are unlikely to affect the general conclusions. First, the data relate to patients screened in 1995/97. Since then blood pressures in UK population-based samples in those aged 65 years or more have declined by, on average, 8.5 mmHg systolic and 9.3 mmHg diastolic in men, and by 9.4 mmHg systolic and 6.1 mmHg diastolic in women. 23 However, part of this decline, if not all of it, will be accounted for by the increase over the same period in the proportion of the sample on treatment with hypertensive medication. This increased between 1995/97 and 2003 from 37.1 to 49.1% in men, and from 42.4 to 52.4% in women. 23 It is unclear if the blood pressure distribution in the untreated population would have changed over this period. Second, the diagnosis of hypertension for known hypertensive patients was based on doctor diagnosis and treatment and, for undiagnosed hypertensives, on the mean of three blood pressure measurements. In the latter case, this depended on the mean of three recent BP measures in the medical record (4221, 94.5%) or the mean of three measures at a screening clinic (293, 6.5%). This is likely to overestimate the number of undiagnosed hypertensives, since there will be an element of regression to the mean, as well as any effect from 'white coat hypertension'. 4 However, our approach is comparable to methods used in earlier studies that have assessed diagnosis and control.
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While we did not have the data for all clinical variables to allow every case to be fully allocated individually to a diagnostic group, data were missing in the minority of cases and were approximated from the best available epidemiological or clinical sources ( Table 2 ).
The new BHS4 guidelines will add only marginally to the population prevalence of hypertension requiring treatment compared with the previous BHS3 guidelines. However, GP workload will undoubtedly increase, as many more patients will now require annual review compared with that using the previous guideline. As for current practice, prescribing costs and GP workload will be greater when adopting BHS4 rather than NICE guidelines. One reason for the difference in prevalence of treatable hypertension is that BHS4 recommends treatment for those with blood pressures of equal to or more than 140/90 mmHg whereas NICE recommend treatment in those with blood pressures greater than 140/90 mmHg. Such subtle differences in criteria can have a marked effect on population prevalence estimates, as demonstrated here, and result in inequitable management decisions for patients. In the present study, 57% of the 180 patients treatable under BHS4 but not under NICE had a systolic blood pressure of 140 mmHg or diastolic blood pressure of 90 mmHg. Accordingly, management decisions will be influenced by the well-known issue of end-digit preference in recording blood pressure 26 though it remains to be seen what difference this will make in the real world of general practice. As well as the impact on clinicians' time running and managing hypertension clinics, the stringent control targets and audit standards associated with each guideline will create further challenges. We did not address this issue in those already receiving treatment because of the historical nature of the data that related to a time when GP decisions were directed by local guidelines. 17 However, the difficulty in meeting blood pressure targets in practice has again been acknowledged following publication of the latest BHS4 guidelines. 27 In addition to all of this, more recent guidance, in particular JNC7, suggests that most patients will require at least dual therapy to control their blood pressure, with consequent implications for costs, patient burden, compliance and side effects.
The latest American JNC7 guidelines 13 suggest that hypertension begins at 140-159/90-99 mmHg with a target of o140/90 mmHg, falling to o130/ 80 mmHg in patients with diabetes or renal disease. These guidelines also introduce the concept of 'prehypertension' at 120-139/80-89 mmHg, concluding that drug treatment should be considered for this group where there are 'compelling indications'. In the present study, we estimated that 124 patients (3.5% of those not on current treatment) would have been eligible for treatment as prehypertensive under JNC7 guidelines but would not have required treatment under BHS4 guidance. This difference partly accounts for the variation in prevalence of treatable hypertension compared with BHS4 and will contribute to differences between international studies of hypertension using dissimilar definitions. The BHS4 guidance acknowledges that blood pressure control, as defined, will be difficult to attain in certain patients, even with maximum therapy. One is left wondering whether this policy is appropriate and realistic. The evidence base, from the perspective of clinical effectiveness, seems broadly sound, particularly as it is rooted in absolute risks rather than blood pressure alone. However, practices wishing to implement the new guidelines may well have to consider where to put their initial energies and resources, and identify which are the first patient groups to target. How much should recalcitrant blood pressure control be pursued? Will commissioning organisations such as Primary Care Trusts (PCTs) in the UK be prepared, or able, to fund the likely growth in activity and drug costs?
Furthermore, in the current context of shared and informed decision making, 28 there is increasing recognition of the need to incorporate patient views. If hypertensive patients are engaged in such decision making, it is not clear what their treatment preferences will be nor whether they will coincide with the guideline recommendations. 29 Patient engagement in decision making in examples of preventive therapies such as hypertension may well not be consistent with maximizing population health gain in terms of cardiovascular events prevented. Patients may take a different view on the balance of benefits (in terms of long-term outcomes) with the immediate, short-term risks and disbenefits (including the problems of regular medication and follow-up).
We hope the estimates in this study will generate what we believe to be a necessary wider debate about the implications of the new guidelines and their inclusion within health policy initiatives and targets. There is a real possibility that services are being set up to fail to deliver admirably argued improvements in the face of the realities of clinical practice, the economic implications of expansion of treatment and control, and possibly the views and attitudes of patients themselves, particularly as we increasingly engage them in open discussion about the absolute risks and benefits of treatments in preventive medicine.
What is known on this topic Guidelines have been promoted as a means of improving hypertension detection, treatment and control but recently they have got more complicated, use multiple risk factor approaches, have reduced thresholds for both diagnosis and treatment and differ in their recommendations. Concerns have been expressed about the potential impact of these guidelines on both patients and practice, but the actual impact of the most recent guidelines has not been assessed using a representative population What this study adds Using recent recommended guidelines, the prevalence of hypertension in those aged over 65 years exceeds 67%. Current USA and UK guidelines differ in their implications for the prevalence of treatable hypertension in those aged over 65 years and both have significant implications for practice workload and for patients. The impact on UK primary care prescribing costs and workload will be greater from implementation of BHS4 than NICE (2004) guidelines
